RU2015134422A - Применение левоцитиризина и монтелукаста при лечении васкулита - Google Patents
Применение левоцитиризина и монтелукаста при лечении васкулита Download PDFInfo
- Publication number
- RU2015134422A RU2015134422A RU2015134422A RU2015134422A RU2015134422A RU 2015134422 A RU2015134422 A RU 2015134422A RU 2015134422 A RU2015134422 A RU 2015134422A RU 2015134422 A RU2015134422 A RU 2015134422A RU 2015134422 A RU2015134422 A RU 2015134422A
- Authority
- RU
- Russia
- Prior art keywords
- vasculitis
- active agent
- administered
- combination
- montelukast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (22)
1. Способ лечения васкулита у нуждающегося в этом пациента, включающий введение эффективного количества комбинации левоцетиризина и монтелукаста.
2. Способ по п. 1, отличающийся тем, что васкулит представляет собой васкулит мелких сосудов.
3. Способ по п. 1, отличающийся тем, что васкулит представляет собой васкулит средних сосудов.
4. Способ по п. 1, отличающийся тем, что васкулит представляет собой васкулит крупных сосудов.
5. Способ по п. 2, отличающийся тем, что васкулит мелких сосудов включает васкулит, ассоциируемый с антинейтрофильными цитоплазматическими антителами.
6. Способ по п. 2, отличающийся тем, что васкулит мелких сосудов включает васкулит, не ассоциируемый с антинейтрофильными цитоплазматическими антителами.
7. Способ по п. 1, отличающийся тем, что васкулит включает пурпуру Шенлейна-Геноха.
8. Способ по п. 1, отличающийся тем, что васкулит включает синдром Черджа-Стросс.
9. Способ по п. 1, отличающийся тем, что указанную комбинацию вводят последовательным образом.
10. Способ по п. 1, отличающийся тем, что указанную комбинацию вводят по существу одновременно.
11. Способ по п. 1, отличающийся тем, что указанную комбинацию вводят при возникновении симптомов.
12. Способ по п. 1, отличающийся тем, что указанную комбинацию вводят пациенту одним или более путей из группы, состоящей из энтерального, внутривенного, внутрибрюшинного, ингаляционного, внутримышечного, подкожного и перорального путей.
13. Способ по п. 1, отличающийся тем, что левоцитиризин и монтелукаст вводят одинаковым путем.
14. Способ по п. 1, отличающийся тем, что указанную комбинацию вводят при возникновении симптомов.
15. Способ по пп. 1-4, дополнительно включающий введение активного агента.
16. Способ по п. 15, отличающийся тем, что указанный активный агент представляет собой глюкокортикоид.
17. Способ по п. 15, отличающийся тем, что указанный активный агент представляет собой стероидный противовоспалительный агент.
18. Способ по п. 15, отличающийся тем, что указанный активный агент представляет собой нестероидный противовоспалительный агент.
19. Способ по п. 15, отличающийся тем, что указанный активный агент представляет собой антигистамин.
20. Способ по п. 15, отличающийся тем, что указанный активный агент представляет собой цитотоксическое лекарственное средство.
21. Способ по п. 15, отличающийся тем, что указанный активный агент представляет собой иммунодепрессивный агент.
22. Способ по п. 15, отличающийся тем, что указанный активный агент представляет собой моноклональное антитело.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780380P | 2013-03-13 | 2013-03-13 | |
| US61/780,380 | 2013-03-13 | ||
| PCT/US2014/021723 WO2014164285A2 (en) | 2013-03-13 | 2014-03-07 | Use of levocetirizine and montelukast in the treatment of vasculitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015134422A true RU2015134422A (ru) | 2017-04-18 |
Family
ID=51659295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015134422A RU2015134422A (ru) | 2013-03-13 | 2014-03-07 | Применение левоцитиризина и монтелукаста при лечении васкулита |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9669025B2 (ru) |
| EP (1) | EP2968309A4 (ru) |
| JP (1) | JP2016512262A (ru) |
| KR (1) | KR20160125283A (ru) |
| CN (1) | CN105263579B (ru) |
| AU (1) | AU2014249534B2 (ru) |
| CA (1) | CA2901413A1 (ru) |
| MX (1) | MX2015011905A (ru) |
| RU (1) | RU2015134422A (ru) |
| WO (1) | WO2014164285A2 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2582373A4 (en) | 2010-06-16 | 2013-10-30 | Bruce Chandler May | USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION |
| ES2745041T3 (es) | 2013-03-13 | 2020-02-27 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios |
| AU2014249534B2 (en) | 2013-03-13 | 2018-08-30 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| RU2672871C2 (ru) | 2013-03-13 | 2018-11-20 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцетиризина и монтелукаста при лечении травматических повреждений |
| EP3193875B1 (en) | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| EP3585809A4 (en) * | 2017-01-30 | 2021-02-24 | Western New England University | THIOLISOMERASE INHIBITORS AND USES THEREOF |
| CN110169969B (zh) * | 2019-06-28 | 2022-05-27 | 南京医科大学 | Mk571在制备预防和治疗心脏病药物中应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801612A (en) | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
| US5211958A (en) | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US5147637A (en) | 1988-06-07 | 1992-09-15 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
| CA2123494A1 (en) | 1991-11-14 | 1993-05-27 | Ernest G. Schutt | Method and apparatus for partial liquid ventilation using fluorocarbons |
| JPH09510952A (ja) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
| IL131025A0 (en) | 1997-01-24 | 2001-01-28 | Autoimmune Inc | Treatment of autoimmune disease using tolerization in combination with methotrexate |
| EP1041990B1 (en) | 1997-12-23 | 2006-06-28 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| BR0112818A (pt) | 2000-07-28 | 2004-10-19 | Immupharm Aps | Processo de tratamento de sintomas do resfriado comum, rinite alérgica e infecções relacionadas com o trato respiratório |
| US7718198B2 (en) | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
| ATE432068T1 (de) | 2001-06-28 | 2009-06-15 | Ucb Farchim Sa | Cetirizin und pseudoephedrin enthaltende tablette |
| CA2452361A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| AU2003232805A1 (en) | 2002-05-24 | 2003-12-12 | Carl-Fr. Coester | Pharmaceutical active substance combination and the use thereof |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| WO2004080414A2 (en) | 2003-03-12 | 2004-09-23 | Mullally John P | Composition and method for treating inflammations by reducing c-reactive protein |
| US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| WO2006010283A1 (en) | 2004-07-28 | 2006-02-02 | Universität Zürich | Prevention and treatment of thrombus formation |
| SG165344A1 (en) * | 2004-10-05 | 2010-10-28 | Genentech Inc | Method for treating vasculitis |
| US20070244128A1 (en) | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2007056510A2 (en) | 2005-11-09 | 2007-05-18 | The Children's Hospital Of Philadelphia | Chloride transport upregulation for the treatment of traumatic brain injury |
| PL1971369T3 (pl) | 2005-12-21 | 2010-01-29 | Meda Pharma Gmbh & Co Kg | Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych |
| US7589076B2 (en) | 2006-05-18 | 2009-09-15 | Pgx Health, Llc | Substituted aryl piperidinylalkynyladenosines as A2AR agonists |
| EP2559434A3 (en) | 2007-02-12 | 2013-05-29 | Mike Nicolaou | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
| WO2008106429A2 (en) | 2007-02-26 | 2008-09-04 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of heart failure and other disorders |
| US20110230496A1 (en) | 2007-08-15 | 2011-09-22 | Chemagis Ltd. | Novel process for preparing highly pure levocetirizine and salts thereof |
| AU2008316284A1 (en) | 2007-10-25 | 2009-04-30 | Merck Frosst Canada Ltd. | Novel crystalline salts of montelukast |
| MX2010004563A (es) | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular. |
| US20090227018A1 (en) | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| NZ595492A (en) | 2009-03-02 | 2013-07-26 | Generics Uk Ltd | Improved Process for the Preparation of Lenalidomide |
| WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| CA2786888A1 (en) | 2010-01-28 | 2011-08-04 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions for the treatment of pain and other indications |
| EP2582373A4 (en) | 2010-06-16 | 2013-10-30 | Bruce Chandler May | USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION |
| WO2012013566A1 (en) | 2010-07-28 | 2012-02-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and inflammatory diseases |
| TR201009398A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Fiziksel özellikleri geliştirilmiş tablet formülasyonları |
| EP2658538A2 (en) | 2010-12-30 | 2013-11-06 | M.D. Ziv Harish | Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables |
| US20130030009A1 (en) | 2010-12-30 | 2013-01-31 | Ziv Harish | Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen |
| CN103561722A (zh) | 2011-04-13 | 2014-02-05 | 利发利希奥公司 | 用于抑制和／或调整炎性神经变性疾病中涉及到的效应t细胞的组合物和方法 |
| EP2520292A1 (en) * | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders |
| KR20130009553A (ko) | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| AU2012288969B2 (en) | 2011-07-26 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Substituted quinolines and their use as medicaments |
| CN102895661A (zh) | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| BR112014024287A2 (pt) | 2012-03-27 | 2018-05-08 | Duke University | composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos |
| CN103505731A (zh) | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| WO2014090990A1 (en) | 2012-12-13 | 2014-06-19 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
| AU2014249534B2 (en) | 2013-03-13 | 2018-08-30 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| ES2745041T3 (es) | 2013-03-13 | 2020-02-27 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios |
| RU2672871C2 (ru) | 2013-03-13 | 2018-11-20 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцетиризина и монтелукаста при лечении травматических повреждений |
| CA2901411A1 (en) | 2013-03-13 | 2014-10-09 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of anaphylaxis |
| EP3193875B1 (en) | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| EP3463324A4 (en) | 2016-06-03 | 2020-01-29 | Irr, Inc. | LEVOCETTIRIZINE AND MONTELUKAST IN THE TREATMENT OF MEDIATED CONDITIONS OF MEDIA BY EXPOSURE TO RADIATION |
-
2014
- 2014-03-07 AU AU2014249534A patent/AU2014249534B2/en active Active
- 2014-03-07 KR KR1020157027767A patent/KR20160125283A/ko not_active Application Discontinuation
- 2014-03-07 JP JP2016500818A patent/JP2016512262A/ja active Pending
- 2014-03-07 CA CA2901413A patent/CA2901413A1/en not_active Abandoned
- 2014-03-07 EP EP14779115.6A patent/EP2968309A4/en not_active Withdrawn
- 2014-03-07 WO PCT/US2014/021723 patent/WO2014164285A2/en active Application Filing
- 2014-03-07 MX MX2015011905A patent/MX2015011905A/es unknown
- 2014-03-07 CN CN201480013797.7A patent/CN105263579B/zh active Active
- 2014-03-07 RU RU2015134422A patent/RU2015134422A/ru unknown
-
2015
- 2015-08-20 US US14/831,100 patent/US9669025B2/en active Active
-
2017
- 2017-05-02 US US15/584,499 patent/US10206919B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014249534B2 (en) | 2018-08-30 |
| US10206919B2 (en) | 2019-02-19 |
| WO2014164285A2 (en) | 2014-10-09 |
| EP2968309A2 (en) | 2016-01-20 |
| CA2901413A1 (en) | 2014-10-09 |
| EP2968309A4 (en) | 2016-08-31 |
| JP2016512262A (ja) | 2016-04-25 |
| CN105263579B (zh) | 2020-01-10 |
| AU2014249534A1 (en) | 2015-08-27 |
| MX2015011905A (es) | 2016-01-08 |
| KR20160125283A (ko) | 2016-10-31 |
| CN105263579A (zh) | 2016-01-20 |
| WO2014164285A3 (en) | 2015-10-29 |
| US20150352101A1 (en) | 2015-12-10 |
| US9669025B2 (en) | 2017-06-06 |
| US20170231980A1 (en) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| JP2014111603A5 (ru) | ||
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| JP2017149726A5 (ru) | ||
| JP2017048208A5 (ru) | ||
| JP2016518387A5 (ru) | ||
| EA201000018A1 (ru) | Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
| BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| JP2016529255A5 (ru) | ||
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| JP2012518624A5 (ru) | ||
| JP2013155188A5 (ru) | ||
| EA201990425A1 (ru) | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение | |
| AR095372A1 (es) | Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| GB2496794A (en) | Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract | |
| CO2017008395A2 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol | |
| RU2015134418A (ru) | Применение левоцетиризина и монтелукаста при лечении анафилаксии | |
| RU2015134423A (ru) | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| RU2015134421A (ru) | Применение левоцетиризина и монтелукаста при лечении травматических повреждений | |
| RU2018125622A (ru) | Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза |